The new device was designed to remove thrombi and emboli from peripheral arteries ranging from 2 to 4 mm. 

“ACR strongly supports the federal efforts to preserve access to such care,” college Executive VP Cynthia R. Moran told Radiology Business. 

Many did not lose coverage because they were deemed ineligible during the redetermination process, but due to procedural reasons, such as not completing required paperwork.

The goal is to inform users on how to best utilize AI tools while also practicing caution, as many are still in their early stages of deployment and can pose risks. 

Multiple medical devices used during cardiopulmonary bypass and extracorporeal membrane oxygenation procedures have been voluntarily recalled due to issues with their packaging.

Malissa Wood, MD, associate chief of cardiology for diversity and equity at Massachusetts General Hospital, explains the role of health equity in cardiovascular care and what her health system is doing to address it. 

A new analysis reveals that insurers could put between $228 million and $2.15 billion back in taxpayers’ pockets by purchasing a series of generic oncology medications at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

ACR, SIR, ASTRO and others are concerned about about forthcoming cuts in the Medicare Physician Fee Schedule that will impact specialties with high equipment costs.